Matches in Wikidata for { <http://www.wikidata.org/entity/Q83267580> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- Q83267580 description "artículu científicu espublizáu en xineru de 2011" @default.
- Q83267580 description "im Januar 2011 veröffentlichter wissenschaftlicher Artikel" @default.
- Q83267580 description "scientific article published on 21 January 2011" @default.
- Q83267580 description "wetenschappelijk artikel" @default.
- Q83267580 description "наукова стаття, опублікована в січні 2011" @default.
- Q83267580 name "Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007" @default.
- Q83267580 name "Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007" @default.
- Q83267580 type Item @default.
- Q83267580 label "Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007" @default.
- Q83267580 label "Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007" @default.
- Q83267580 prefLabel "Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007" @default.
- Q83267580 prefLabel "Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007" @default.
- Q83267580 P1104 Q83267580-3E5EDEF8-BA7B-47E3-A210-5FBEED3132C9 @default.
- Q83267580 P1433 Q83267580-5188FE15-3A92-4976-984D-5F7D6DA65217 @default.
- Q83267580 P1476 Q83267580-5B47A63C-392D-4416-B304-39CB0E881BB4 @default.
- Q83267580 P2093 Q83267580-4C7B7F0B-E008-4EAA-A772-D2611AE225C6 @default.
- Q83267580 P2093 Q83267580-7BB5F396-B134-4244-89CB-468557C506B6 @default.
- Q83267580 P2093 Q83267580-7E501890-5279-4686-9D9D-1588911021B9 @default.
- Q83267580 P2093 Q83267580-87E06116-6F80-48F7-92C6-A947E5CF5ACD @default.
- Q83267580 P2093 Q83267580-8A55E692-CC65-4D80-A69B-8813CE7E0111 @default.
- Q83267580 P2093 Q83267580-9D74396E-2287-4891-A3B4-2360E2D4808D @default.
- Q83267580 P2093 Q83267580-DAF533CE-9D1D-46EE-A591-63DA2F8B604B @default.
- Q83267580 P2093 Q83267580-F6359C9B-403E-4703-B4BF-6CD1CEC3B9C0 @default.
- Q83267580 P2860 Q83267580-0D29DE5A-CA6A-4FAF-B032-65D2592A6024 @default.
- Q83267580 P2860 Q83267580-179AFC7D-8771-49D1-92FC-36B401F63F61 @default.
- Q83267580 P2860 Q83267580-18CC5457-4359-418B-A998-9F880F66E142 @default.
- Q83267580 P2860 Q83267580-3889437E-7CE0-4DF4-AE6D-6E28149020B5 @default.
- Q83267580 P2860 Q83267580-5C563D49-1BFA-456A-B4AE-486D4CDCFE52 @default.
- Q83267580 P2860 Q83267580-68BCE4BD-7BD1-43B7-8198-D6A463EC50EC @default.
- Q83267580 P2860 Q83267580-6CDE6BDF-5FB7-4205-BE3B-26323D4E97FB @default.
- Q83267580 P2860 Q83267580-6F6E8D44-46FA-4300-8002-3641879221F1 @default.
- Q83267580 P2860 Q83267580-704C302E-4109-4C55-A45C-ACC5F27CF2FC @default.
- Q83267580 P2860 Q83267580-7B4E53C6-9E03-4EC6-B31C-DA453C1D0F5C @default.
- Q83267580 P2860 Q83267580-83528EFE-AD84-4D62-97C8-C53CD5FB3E5B @default.
- Q83267580 P2860 Q83267580-9552A81F-C18D-430A-A0B7-DF64DFB280F6 @default.
- Q83267580 P2860 Q83267580-9EEB9987-DE09-4EA0-B82D-8AE7888272CD @default.
- Q83267580 P2860 Q83267580-A29B1F88-5A47-41CB-AF77-63B6CCCD38BD @default.
- Q83267580 P2860 Q83267580-B1346841-465D-4256-BEF1-5A7EFC697553 @default.
- Q83267580 P2860 Q83267580-BD6BA5EE-1637-47D1-BC6B-2FC3A0CED3F6 @default.
- Q83267580 P2860 Q83267580-C9AFC191-A83F-496D-88A3-AAD964E3D51C @default.
- Q83267580 P2860 Q83267580-CD95F983-D25F-4BFD-8D56-CF9A60127C62 @default.
- Q83267580 P2860 Q83267580-D5225D1A-DD09-4A89-951F-A7854EBE7153 @default.
- Q83267580 P2860 Q83267580-E360C5AC-C3BD-41B7-9CD9-0DD8AF33C482 @default.
- Q83267580 P2860 Q83267580-ED132B20-E9AD-4CD6-8614-CE6841D57AE1 @default.
- Q83267580 P304 Q83267580-F55BF014-1106-44C3-9742-1A429EB5E4CB @default.
- Q83267580 P31 Q83267580-4245C553-2C4D-45C7-8811-94D729BD346B @default.
- Q83267580 P356 Q83267580-2B42B6D9-0CC5-4B3F-BECD-5861F9FFE994 @default.
- Q83267580 P433 Q83267580-A5F88D62-06CB-4247-B4E9-71A01F3B895E @default.
- Q83267580 P478 Q83267580-4A3FE64A-3B48-49CE-A070-4E97B5C81A61 @default.
- Q83267580 P50 Q83267580-43D17593-86F7-4829-A9E3-C848EFE6662E @default.
- Q83267580 P577 Q83267580-8F066BCC-D22C-49F1-A529-B6BB0759379E @default.
- Q83267580 P698 Q83267580-F33FE9C5-0665-4A4D-9C32-1AE52BFA0F92 @default.
- Q83267580 P921 Q83267580-0C8C72AD-3DDB-4157-A91E-418A3EF10A19 @default.
- Q83267580 P921 Q83267580-8D8F37FB-DB60-443B-8452-64447FD6F47C @default.
- Q83267580 P921 Q83267580-95E631B3-535F-49D9-8E3B-A436C28E80FA @default.
- Q83267580 P356 J.VACCINE.2011.01.018 @default.
- Q83267580 P698 21256876 @default.
- Q83267580 P1104 "+8" @default.
- Q83267580 P1433 Q7907941 @default.
- Q83267580 P1476 "Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix™) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007" @default.
- Q83267580 P2093 "C C Carlos" @default.
- Q83267580 P2093 "D D Anh" @default.
- Q83267580 P2093 "D V Thiem" @default.
- Q83267580 P2093 "H H Han" @default.
- Q83267580 P2093 "H L Bock" @default.
- Q83267580 P2093 "P V Suryakiran" @default.
- Q83267580 P2093 "S Gatchalian" @default.
- Q83267580 P2093 "Y Hutagalung" @default.
- Q83267580 P2860 Q24605360 @default.
- Q83267580 P2860 Q34275969 @default.
- Q83267580 P2860 Q34550164 @default.
- Q83267580 P2860 Q34984560 @default.
- Q83267580 P2860 Q37405073 @default.
- Q83267580 P2860 Q39591585 @default.
- Q83267580 P2860 Q40398497 @default.
- Q83267580 P2860 Q40634755 @default.
- Q83267580 P2860 Q41875733 @default.
- Q83267580 P2860 Q43634471 @default.
- Q83267580 P2860 Q44881283 @default.
- Q83267580 P2860 Q45039647 @default.
- Q83267580 P2860 Q45151550 @default.
- Q83267580 P2860 Q46232575 @default.
- Q83267580 P2860 Q50801422 @default.
- Q83267580 P2860 Q56787285 @default.
- Q83267580 P2860 Q56995254 @default.
- Q83267580 P2860 Q57530944 @default.
- Q83267580 P2860 Q74600831 @default.
- Q83267580 P2860 Q79958029 @default.
- Q83267580 P2860 Q82673369 @default.
- Q83267580 P304 "2029-2036" @default.
- Q83267580 P31 Q13442814 @default.
- Q83267580 P356 "10.1016/J.VACCINE.2011.01.018" @default.
- Q83267580 P433 "11" @default.
- Q83267580 P478 "29" @default.
- Q83267580 P50 Q56862574 @default.
- Q83267580 P577 "2011-01-21T00:00:00Z" @default.
- Q83267580 P698 "21256876" @default.
- Q83267580 P921 Q4411598 @default.
- Q83267580 P921 Q881 @default.
- Q83267580 P921 Q928 @default.